Australia: AstraZeneca Runs Out Of Puff

Last Updated: 23 March 2006
Article by Wayne Condon

The "Seretide" war reached the Full Court of the Federal Court in Australia this month. The central issue in the case involved the question of whether two flyers sent to some 14,000 general practitioners in Australia and two advertisements published in "Australian Doctor" magazine relating to Glaxo's "Seretide" combination inhaler were misleading and deceptive or likely to mislead or deceive in contravention of the Australian Trade Practices Act.

The flyers and the advertisements all sought to promote the prescription by doctors of Glaxo's combination inhaler for the control of asthma either under the name "Seretide" or "Seretide Total Control". Each of the flyers and advertisements referred to an article published in the American Journal of Respiratory and Critical Care Medicine. That article reported on the findings of a study known as the "Goal" study. The study related to the control of asthma with a combination Salmeterol/Fluticasone treatment.

AstraZeneca complained that Glaxo had made a number of misrepresentations in the flyers and the advertisements namely:

  1. that all or virtually all asthma patients will achieve 100% control or total control of all asthma symptoms by using Seretide;
  2. that a majority (ie greater than 50%) of all asthma patients will achieve 100% control or total control of all asthma symptoms by using Seretide;
  3. that a sufficiently high proportion of all asthma patients will achieve 100% control or total control of all asthma symptoms by using Seretide to justify the use of the brand slogan "Seretide total control";
  4. that 41% of all patients taking part in the study known as the "Gaining Optimal Asthma Control" study published in the American Journal of Respiratory and Critical Care Medicine in 2004 (Goal study) achieved 100% control of all asthma symptoms by using Seretide;
  5. that 41% of all patients taking part in the Goal study achieved "total control" (as that term is defined in the Seretide advertisements) of all asthma symptoms by using Seretide;
  6. that 71% of all patients taking part in the Goal study achieved "well controlled asthma" (as that term is defined in the Seretide advertisements) of all asthma symptoms by using Seretide; and
  7. that the patient results of the Goal study identified in paragraphs (d) (e) and (f) will be likely to be achieved in clinical practice.

At first instance the judge had dismissed all of AstraZeneca's complaints. The Full Court noted that:

  1. Each of the flyers and advertisements complained about referred to the article report of the Goal study published in the American Journal of Respiratory and Critical Care Medicine and bore an endorsement in or to the following effect:

  3. In each instance where the expression "Seretide Total Control" had been used in the flyers and advertisements, an asterisk had been added directing the reader's attention to a footnote summarising the Goal study.
  4. The footnotes appeared in an easy to read type size on each of the original documents.

The Full Court held that, in determining whether there had been a contravention of the Trade Practices Act, it was necessary for the court to determine whether or not the conduct complained of amounted to a representation which has or would be likely to lead to a misconception arising in the minds of that section of the public to whom the conduct has been directed.

The Full Court followed previous authority to the effect that an asterisk can be sufficient to draw the attention of a consumer to a qualification of a representation however the qualifying material must be sufficiently prominent to prevent the primary statement from being misleading and deceptive or likely to mislead and deceive.

Viewing each of the flyers and advertisements as marketing documents directed by Glaxo to ordinary or reasonable members of the community of general practitioners throughout Australia the Full Court was unable to find that any of them made the representations alleged by AstraZeneca.

It was held that the term "Seretide Total Control" was, in effect, an alternative brand name adopted by Glaxo for its Seretide medication. In any event, the footnotes were sufficient to overcome any misrepresentation that might otherwise have arisen.

The difficulty for AstraZeneca was that it was forced to concede that the qualified statements made about Seretide were, in fact, true.

This left the Full Court with the alleged representation that each of the flyers and advertisements represented to ordinary or reasonable members of the community of general practitioners throughout Australia that;

"the patient results of the Goal study ... will be achieved or will be likely to be achieved in clinical practice".

AstraZeneca's position in relation to this alleged representation was that, while it conceded the truth of the matters represented by the flyers and the advertisements to which the 41% and 71% figures related it did so only in "an absolute statistical sense". It argued that the references to the Goal study in the flyers and the advertisements were deficient in that they failed to point out that the Goal study did not include patients with significant related diseases, smokers and patients under the age of 12 years. Although the Full Court accepted that the flyers and advertisements did not include any such qualification, it also found that there was no representation that the Goal study patients were representative of the asthma suffering members of the community at large.

Consequently, AstraZeneca failed to establish any of the alleged misrepresentations it asserted Glaxo had made.


This case, once again, emphasises that advertisements and promotional material need to be considered in context and from the viewpoint of the likely effect of the advertisement or promotion on ordinary and reasonable members of the section of the community towards whom the conduct has been directed. In the case of advertising and promotion to medical practitioners who are a sophisticated and highly qualified section of the community, it may take more to establish a misrepresentation.

Where complaint is made of implied misrepresentations said to arise in the course of advertising or promotion of a product, considerable care needs to be exercised before commencing litigation. One can only observe that the total vindication of Glaxo's position in this case only allowed it to strengthen its marketing position in relation to Seretide.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.